**Supplementary table 1.** Achievement of ≥50% reduction in MMD during the OLEP: shift table by treatment arm and responder status during the DBTP (open-label analysis set)

<table>
<thead>
<tr>
<th>Criteria for DBTP</th>
<th>Percentage of OLEP visits reaching 50% responder criteria among visits with non-missing MMD values</th>
<th>Patients on erenumab 140 mg in DBTP who continued erenumab in OLEP</th>
<th>Patients on placebo in DBTP who switched to erenumab in OLEP</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 visit with 50% response</td>
<td>62</td>
<td>24 (38.7)</td>
<td>19 (30.6)</td>
</tr>
<tr>
<td>1 visit with 50% response</td>
<td>27</td>
<td>6 (22.2)</td>
<td>13 (48.1)</td>
</tr>
<tr>
<td>2 visits with 50% response</td>
<td>17</td>
<td>1 (5.9)</td>
<td>14 (82.4)</td>
</tr>
<tr>
<td>3 visits with 50% response</td>
<td>12</td>
<td>0</td>
<td>11 (91.7)</td>
</tr>
<tr>
<td>≥1 visit with 50% response</td>
<td>56</td>
<td>7 (12.5)</td>
<td>38 (67.9)</td>
</tr>
<tr>
<td>≥2 visits with 50% response</td>
<td>29</td>
<td>1 (3.4)</td>
<td>25 (86.2)</td>
</tr>
<tr>
<td>50% responder at Week 12 only</td>
<td>10</td>
<td>1 (10.0)</td>
<td>8 (80.0)</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
50% responder is defined as achievement of ≥50% reduction in MMD.

<table>
<thead>
<tr>
<th>50% responder at week 12 and ≥1 other visit</th>
<th>25</th>
<th>1 (4.0)</th>
<th>21 (84.0)</th>
<th>17 (68.0)</th>
<th>13 (52.0)</th>
<th>10 (40.0)</th>
<th>11</th>
<th>0</th>
<th>11 (100)</th>
<th>9 (81.8)</th>
<th>6 (54.5)</th>
<th>5 (45.5)</th>
</tr>
</thead>
</table>

DBTP, double-blind treatment phase; MMD, monthly migraine days; OLEP, open-label extension phase
# Supplementary appendix 1

## List of Independent Ethics Committees (IEC) or Institutional Review Boards (IRB) by study centre

<table>
<thead>
<tr>
<th>Centre No.</th>
<th>Ethics Committee or Institutional Review Board</th>
<th>Department / Organization</th>
<th>City, State/Province, Postal Code</th>
<th>Country</th>
<th>IRB/IEC Approval number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1003</td>
<td>Austin Health Human Research Ethics Committee</td>
<td>Office for Research</td>
<td>Heidelberg</td>
<td>Victoria 3084</td>
<td>Australia HREC/16/AUSTIN/398</td>
</tr>
<tr>
<td>1021</td>
<td>Commissie voor Medische Ethiek UZ Gent</td>
<td>Commissie Medische Ethiek</td>
<td>Gent 9000</td>
<td>Belgium</td>
<td>2016/290</td>
</tr>
<tr>
<td>1022</td>
<td>Commissie voor Medische Ethiek UZ Gent</td>
<td>Commissie Medische Ethiek</td>
<td>Gent 9000</td>
<td>Belgium</td>
<td>2016/290</td>
</tr>
<tr>
<td>1023</td>
<td>Commissie voor Medische Ethiek UZ Gent</td>
<td>Commissie Medische Ethiek</td>
<td>Gent 9000</td>
<td>Belgium</td>
<td>2016/290</td>
</tr>
<tr>
<td>1024</td>
<td>Commissie voor Medische Ethiek UZ Gent</td>
<td>Commissie Medische Ethiek</td>
<td>Gent 9000</td>
<td>Belgium</td>
<td>2016/290</td>
</tr>
<tr>
<td>1031</td>
<td>Etická komise IKEM a TN, Thomayerova nemocnice</td>
<td>Vídeňská 800</td>
<td>Praha 4 140 59</td>
<td>Czech Republic</td>
<td>M-16-50</td>
</tr>
<tr>
<td>1033</td>
<td>Etická komise IKEM a TN, Thomayerova nemocnice</td>
<td>Vídeňská 800</td>
<td>Praha 4 140 59</td>
<td>Czech Republic</td>
<td>M-16-50</td>
</tr>
<tr>
<td>1034</td>
<td>Etická komise IKEM a TN, Thomayerova nemocnice</td>
<td>Vídeňská 800</td>
<td>Praha 4 140 59</td>
<td>Czech Republic</td>
<td>M-16-50</td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code, Country</td>
<td>IRB/IEC Approval number</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>1041</td>
<td>De Videnskabsetiske Komiteer for Region Hovedstaden</td>
<td>Regionsgården, Center for sundheds, Kongens Vænge 2</td>
<td>Hillerød 3400 Denmark</td>
<td>H-16038336</td>
<td></td>
</tr>
<tr>
<td>1051</td>
<td>Varsinais-Suomen eettinen toimikunta</td>
<td>Turku 20521</td>
<td>Finland</td>
<td>EC dniro 101/1800/2016</td>
<td></td>
</tr>
<tr>
<td>1053</td>
<td>Varsinais-Suomen eettinen toimikunta</td>
<td>Turku 20521</td>
<td>Finland</td>
<td>EC dniro 101/1800/2016</td>
<td></td>
</tr>
<tr>
<td>1054</td>
<td>Varsinais-Suomen eettinen toimikunta</td>
<td>Turku 20521</td>
<td>Finland</td>
<td>EC dniro 101/1800/2016</td>
<td></td>
</tr>
<tr>
<td>1061</td>
<td>Comite de protection des personnes Sud Mediterranee I</td>
<td>Marseille 13274</td>
<td>France</td>
<td>16 89 MS 3</td>
<td></td>
</tr>
<tr>
<td>1063</td>
<td>Comite de protection des personnes Sud Mediterranee I</td>
<td>Marseille 13274</td>
<td>France</td>
<td>16 89 MS 3</td>
<td></td>
</tr>
<tr>
<td>1065</td>
<td>Comite de protection des personnes Sud Mediterranee I</td>
<td>Marseille 13274</td>
<td>France</td>
<td>16 89 MS 3</td>
<td></td>
</tr>
<tr>
<td>1071</td>
<td>Landesamt für Gesundheit und Soziales, Ethik-Kommission des Landes Berlin</td>
<td>Berlin 10707</td>
<td>Germany</td>
<td>16/0297 – EK 15</td>
<td></td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code</td>
<td>Country</td>
<td>IRB/IEC Approval number</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>----------------------------------</td>
<td>---------</td>
<td>------------------------</td>
</tr>
<tr>
<td>1072</td>
<td>Ludwig-Maximilians-Universität München, Medizinische Fakultät Ethikkommission</td>
<td>München 80336, Germany</td>
<td></td>
<td></td>
<td>16/0297 – EK 15</td>
</tr>
<tr>
<td>1073</td>
<td>Christian-Albrechts-Universität zu Kiel, Ethik-Kommission der Medizinischen Fakultät</td>
<td>Kiel 24105, Germany</td>
<td></td>
<td></td>
<td>16/0297 – EK 15</td>
</tr>
<tr>
<td>1074</td>
<td>Arztekammer Hamburg, Geschäftsstelle der Ethik-Kommission</td>
<td>Hamburg 22083, Germany</td>
<td></td>
<td></td>
<td>16/0297 – EK 15</td>
</tr>
<tr>
<td>1075</td>
<td>Landesärztekammer Hessen, Ethik-Kommission</td>
<td>Frankfurt am Main 60488, Germany</td>
<td></td>
<td></td>
<td>16/0297 – EK 15</td>
</tr>
<tr>
<td>1076</td>
<td>Landesamt für Gesundheit und Soziales, Ethik-Kommission des Landes Berlin</td>
<td>Berlin 10707, Germany</td>
<td></td>
<td></td>
<td>16/0297 – EK 15</td>
</tr>
<tr>
<td>1077</td>
<td>Sächsische Landesärztekammer, Ethik-Kommission</td>
<td>Dresden 01099, Germany</td>
<td></td>
<td></td>
<td>16/0297 – EK 15</td>
</tr>
<tr>
<td>1078</td>
<td>Universitätsklinikum Essen, Medizinische Fakultät der Universität Duisburg-Essen Ethik-Kommission</td>
<td>Essen 45147, Germany</td>
<td></td>
<td></td>
<td>16/0297 – EK 15</td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code</td>
<td>Country</td>
<td>IRB/IEC Approval number</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>---------</td>
<td>------------------------</td>
</tr>
<tr>
<td>1079</td>
<td>Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen</td>
<td>Tübingen 72074</td>
<td>Germany</td>
<td>16/0297 – EK 15</td>
<td></td>
</tr>
<tr>
<td>1081</td>
<td>Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität</td>
<td>Münster 48147</td>
<td>Germany</td>
<td>16/0297 – EK 15</td>
<td></td>
</tr>
<tr>
<td>1082</td>
<td>Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster</td>
<td>Münster 48147</td>
<td>Germany</td>
<td>16/0297 – EK 15</td>
<td></td>
</tr>
<tr>
<td>1084</td>
<td>Friedrich-Alexander-Universität Erlangen-Nürnberg, Medizinische Fakultät Ethik-Kommission</td>
<td>Erlangen 91054</td>
<td>Germany</td>
<td>16/0297 – EK 15</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>National Ethics Committee, Cholargos Attica</td>
<td>15562</td>
<td>Greece</td>
<td>62648/2018, dated 18-Jun-2018</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>National Ethics Committee, Cholargos Attica</td>
<td>15562</td>
<td>Greece</td>
<td>62648/2018, dated 18-Jun-2018</td>
<td></td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code, Country</td>
<td>IRB/IEC Approval number</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------</td>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>National Ethics Committee</td>
<td>Cholargos Attica 15562, Greece</td>
<td>62648/2018, dated 18-Jun-2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>Comitato Etico dell'Università Sapienza</td>
<td>Policlinico Universitario Umberto I</td>
<td>Roma 00161, Italy 10151</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code</td>
<td>Country</td>
<td>IRB/IEC Approval number</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------------</td>
<td>-----------------------------</td>
<td>----------------------------------</td>
<td>---------</td>
<td>------------------------</td>
</tr>
<tr>
<td>2015</td>
<td>Comitato Etico Seconda Università degli Studi di Napoli - Università degli Studi della Campania L. Vanvitelli</td>
<td>AOU SUN- AORN Ospedale dei Colli</td>
<td>Napoli 80138</td>
<td>Italy</td>
<td>2011: 114 SA/2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2012: 2018-147 CINECA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2013: NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2014: 06/2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015: 131/2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2016: 64/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2017: 158-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16131/2018/Em003/AUSLBO</td>
</tr>
<tr>
<td>2016</td>
<td>Comitato Etico Regione Lombardia - Sezione della Fondazione IRCCS</td>
<td>Istituto Neurologico Carlo Besta</td>
<td>Milano 20133</td>
<td>Italy</td>
<td>2011: 114 SA/2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2012: 2018-147 CINECA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2013: NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2014: 06/2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015: 131/2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2016: 64/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2017: 158-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16131/2018/Em003/AUSLBO</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2012: 2018-147 CINECA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2013: NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2014: 06/2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015: 131/2018</td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code, Country</td>
<td>IRB/IEC Approval number</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>2028</td>
<td>METC LUCM Commissie Medische Ethiek</td>
<td>Leiden N/A 2300 PC the Netherlands</td>
<td>NL58509.058.16 CME number: P16.250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2029</td>
<td>METC LUCM Commissie Medische Ethiek</td>
<td>Leiden N/A 2300 PC the Netherlands</td>
<td>NL58509.058.16 CME number: P16.250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2030</td>
<td>METC LUCM Commissie Medische Ethiek</td>
<td>Leiden N/A 2300 PC the Netherlands</td>
<td>NL58509.058.16 CME number: P16.250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2041</td>
<td>Regionale komiteer for medisinsk og helsefaglig forskningsetikk</td>
<td>Oslo 0484 Norway</td>
<td>2016/1429/REK sør-øst B, dated: 18-Jun-2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2051</td>
<td>CEIC Grupo Hospitalario Centro Médico Quirón en Barcelona Teknon</td>
<td>Barcelona Barcelona 08022 Spain</td>
<td>G.3/PROT.HIP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2052</td>
<td>CEIC Grupo Hospitalario Centro Médico Quirón en Barcelona Teknon</td>
<td>Barcelona Barcelona 08022 Spain</td>
<td>G.3/PROT.HIP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2053</td>
<td>CEIC Grupo Hospitalario Centro Médico Quirón en Barcelona Teknon</td>
<td>Barcelona Barcelona 08022 Spain</td>
<td>G.3/PROT.HIP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code</td>
<td>Country</td>
<td>IRB/IEC Approval number</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>---------</td>
<td>------------------------</td>
</tr>
<tr>
<td>2055</td>
<td>CEIC Grupo Hospitalario Quirón en Barcelona</td>
<td>Centro Médico Teknon</td>
<td>Barcelona 08022</td>
<td>Spain</td>
<td>G.3/PROT.HIP</td>
</tr>
<tr>
<td>2056</td>
<td>CEIC Grupo Hospitalario Quirón en Barcelona</td>
<td>Centro Médico Teknon</td>
<td>Barcelona 08022</td>
<td>Spain</td>
<td>G.3/PROT.HIP</td>
</tr>
<tr>
<td>2057</td>
<td>CEIC Grupo Hospitalario Quirón en Barcelona</td>
<td>Centro Médico Teknon</td>
<td>Barcelona 08022</td>
<td>Spain</td>
<td>G.3/PROT.HIP</td>
</tr>
<tr>
<td>2067</td>
<td>Etikprövningsmyndigheten</td>
<td>Uppsala 750 02</td>
<td>Uppsala 750 02</td>
<td>Sweden</td>
<td>2018-122, dated: 27-Jul-2018</td>
</tr>
<tr>
<td>2069</td>
<td>Etikprövningsmyndigheten</td>
<td>Uppsala 750 02</td>
<td>Uppsala 750 02</td>
<td>Sweden</td>
<td>2018-122, dated: 27-Jul-2018</td>
</tr>
<tr>
<td>2070</td>
<td>Etikprövningsmyndigheten</td>
<td>Uppsala 750 02</td>
<td>Uppsala 750 02</td>
<td>Sweden</td>
<td>2018-122, dated: 27-Jul-2018</td>
</tr>
<tr>
<td>2072</td>
<td>Etikprövningsmyndigheten</td>
<td>Uppsala 750 02</td>
<td>Uppsala 750 02</td>
<td>Sweden</td>
<td>2018-122, dated: 27-Jul-2018</td>
</tr>
<tr>
<td>2073</td>
<td>Etikprövningsmyndigheten</td>
<td>Uppsala 750 02</td>
<td>Uppsala 750 02</td>
<td>Sweden</td>
<td>2018-122, dated: 27-Jul-2018</td>
</tr>
<tr>
<td>2081</td>
<td>Kantonale Ethikkommission</td>
<td>Zürich 8090</td>
<td>Zürich</td>
<td>Switzerland</td>
<td>EC Ref no 2016-01326</td>
</tr>
<tr>
<td>2082</td>
<td>Kantonale Ethikkommission</td>
<td>Zürich 8090</td>
<td>Zürich</td>
<td>Switzerland</td>
<td>EC Ref no 2016-01326</td>
</tr>
<tr>
<td>2083</td>
<td>Kantonale Ethikkommission</td>
<td>Zürich 8090</td>
<td>Zürich</td>
<td>Switzerland</td>
<td>EC Ref no 2016-01326</td>
</tr>
<tr>
<td>Centre No.</td>
<td>Ethics Committee or Institutional Review Board</td>
<td>Department / Organization</td>
<td>City, State/Province, Postal Code, Country</td>
<td>IRB/IEC Approval number</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------</td>
<td>-----------------</td>
<td>---------------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>2091</td>
<td>East Midlands - Leicester Central Research Ethics Committee</td>
<td>The Old Chapel, Royal Standard Place</td>
<td>Nottingham NG1 6FS United Kingdom</td>
<td>IRAS: 211113 REC reference: 16/EM/0386</td>
<td></td>
</tr>
<tr>
<td>2092</td>
<td>East Midlands - Leicester Central Research Ethics Committee</td>
<td>The Old Chapel, Royal Standard Place</td>
<td>Nottingham NG1 6FS United Kingdom</td>
<td>IRAS: 211113 REC reference: 16/EM/0386</td>
<td></td>
</tr>
<tr>
<td>2094</td>
<td>East Midlands - Leicester Central Research Ethics Committee</td>
<td>The Old Chapel, Royal Standard Place</td>
<td>Nottingham NG1 6FS United Kingdom</td>
<td>IRAS: 211113 REC reference: 16/EM/0386</td>
<td></td>
</tr>
</tbody>
</table>
Supplementary appendix 2

Inclusion criteria

Patients eligible for inclusion in this study must have fulfilled all of the following criteria. For inclusion purposes, one month equals one calendar month.

During the Screening Epoch:

- Written informed consent was obtained before any assessment was performed
- Adults ≥18 to ≤65 years of age upon entry into screening
- Documented history of migraine (with or without aura) for ≥12 months prior to screening according to the International Classification of Headache Disorders-(ICHD-3 beta)
- 4 to 14 days per month (in at least two separate attacks) of migraine symptoms (based on ICHD-3 criteria) on average across the 3 months prior to screening based on retrospective reporting
- <15 days per month of headache symptoms (i.e., migraine and non-migraine)

Patients must have*:

- Failed 2 to 4 prior migraine prophylaxis treatments out of the following: propranolol/metoprolol, topiramate, flunarizine, valproate/divalproex, amitriptyline, venlafaxine, lisinopril, candesartan, locally approved products (e.g. oxetorone or pizotifen)
- Failed one AND failed or not be suitable for a second of the following:
  - Propranolol OR metoprolol
  - Topiramate
  - Flunarizine

* The following definitions were applicable for inclusion criteria 6-8:
• Efficacy failure was defined as “no meaningful reduction in headache frequency after administration of the respective medication for an adequate period of time (at least 2-3 months are recommended by the European Headache Federation treatment guidelines) at generally accepted therapeutic dose(s) based on the investigator’s assessment within the last 5 years prior to screening.”

• Tolerability failure was defined as “documented discontinuation due to adverse events of the respective medication at any previous time.”

• “Not suitable” for the purpose of this study was defined as “patient was not considered to be suitable for the treatment for medical reasons such as contraindications or precautions included in local labels, national guidelines or other locally binding documents, or other medically relevant reasons” as confirmed by the treating physician.

During the Baseline Epoch:

• Migraine frequency of 4 to 14 migraine days during the Baseline Epoch, confirmed by the eDiary

• ≥80% eDiary compliance during the Baseline Epoch

Exclusion criteria

Patients fulfilling any of the following criteria were not eligible for inclusion in this study. No additional exclusions were applied by the investigator, in order to ensure that the study population was representative of all eligible patients. Calendar months were used for exclusion purposes.

• Older than 50 years of age at migraine onset

• Unable to differentiate migraine from other headaches

• History of cluster headache or hemiplegic migraine headache

• Failed more than 4 prior migraine prophylaxis treatments out of the following:
- Propranolol/metoprolol, topiramate, flunarizine, valproate/divalproex, amitriptyline, venlafaxine, lisinopril, candesartan, locally approved products (e.g. oxetorone or pizotifen)

- Use of a prophylactic migraine medication within 5 half-lives, or a device or procedure within one month prior to the start of the baseline phase or during the baseline phase

- Prior Botulinum toxin A treatment in the head/neck region (including cosmetic use or other licensed indications for Botox®) within 4 months prior to the start of the baseline epoch or during the baseline epoch

- Use of the following for any indication in the 1 month prior to the start of the baseline phase or during the baseline phase:
  - Ergotamines or triptans ≥10 days/month, or
  - Simple analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs], acetaminophen, paracetamol) ≥15 days/month, or
  - Opioid- or butalbital-containing analgesics ≥4 days/month

- Anticipated to require any excluded medication or device (such as occipital nerve stimulators, transcranial magnetic stimulation) during the study

- Active chronic pain syndromes (such as fibromyalgia or chronic pelvic pain)

- History or current evidence of major psychiatric disorder (such as schizophrenia, bipolar disorder or type B personality disorder that might interfere with the ability to properly report clinical outcomes)

- Evidence of drug or alcohol abuse or dependence within 12 months prior to screening, based on medical records or patient self-report

- Current evidence of depression based on a Beck Depression Inventory (BDI)-II total score of >19 at screening. Patients with anxiety disorder and/or major depressive disorder were permitted in the study if they were considered by the investigator to be
stable and were taking no more than one medication per disorder. Patients must have been on a stable dose within the 3 months prior to the start of the baseline phase.

- **History of seizure disorder or other significant neurological conditions other than migraine**

  Score “yes” on item 4 or item 5 of the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C-SSRS), if this ideation occurred in the past 6 months, or “yes” on any item of the Suicidal Behaviour section, except for the “Non-Suicidal Self-Injurious Behaviour” (Item also included in the Suicidal Behaviour section), if this behaviour occurred in the past 2 years.

- **Myocardial infarction, stroke, transient ischemic attack, unstable angina, or coronary artery bypass surgery or other revascularization procedures within 12 months prior to screening**

- **History or current diagnosis of electrocardiogram abnormalities indicating significant risk of safety for patients participating in the study**

- **History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases**

- **Hepatic disease by history or total bilirubin ≥2 x upper limit of normal (ULN) or alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥3.0 x ULN as assessed by central laboratory at initial screening**

- **Pregnant or nursing (lactating) women**

- **Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 110 days after stopping of study medication.**

  Highly effective contraception methods include:

  - Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g. calendar, ovulation, symptothermal,
post-ovulation methods) and withdrawal were not acceptable methods of contraception

- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment

- Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient

- Use of oral (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), e.g. hormone vaginal ring or transdermal hormone contraception

- In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking investigational drug

- Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
• Use of other investigational drugs within 5 half-lives of enrolment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer
• History of hypersensitivity to the study drug or its excipients
• Any prior exposure to investigational products targeting the calcitonin gene-related peptide pathway, including previous erenumab studies
• Unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures (e.g. independent completion of electronic diary items) to the best of the patient’s and investigator’s knowledge.